Our team
Article
|Updated
To achieve the objectives of PainFACT we have on board a solid team of partner institutions, collaborators and personnel with leading expertise within their respective fields.
PainFACT has seven partners, including three from industry (two SMEs) and four academic groups. The academic partners (NIPH, OUH, UPF and UNISTRA) bring extensive experience in human and animal research with expertise and decades of experience in basic, pre-clinical and clinical research of pain and the co-morbidities under study, while the industry partners (TATAA, deCODE and QUIBIM) bring high throughput technologies in genetics, biomarker development, bioinformatics, and machine-learning based image analysis. Together the partners form a compact, fully integrated entity.
|
Norwegian Institute of Public Health (NIPH) |
|
|
Oslo University Hospital (OUH) |
|
| TATAA Biocenter AB (TATAA) TATAA will generate proteome data on biosamples in WP2 (biomarker discovery in humans), and will also participate in WP4 test validation. |
|
| Universitat Pompeu Fabra (UPF) UPF will lead WP3 on biomarker discovery in mice and WP7 on dissemination and exploitation. Further, UPF will be involved in WP5 on validation of biomarkers in mice, WP6 on cross validation and joint analysis, and WP8 regarding ethical issues of animal experiments. |
|
| Islensk Erfdagreining EHF / deCODE genetics (DECODE) DECODE will lead WP 4 on validation of biomarkers in humans and WP6 on cross validation and joint analysis. In addition, DECODE will make major contributions to WP2 on biomarker discovery in humans. |
|
| Université de Strasbourg (UNISTRA) UNISTRA will lead WP5 on validation of biomarkers in mice, and contribute to WP3 on biomarker discovery in mice – both in close cooperation with their linked third party INSERM. |
|
| QUIBIM Sociedad Limitada (QUIBIM) QUIBIM is an SME dedicated to medical image post-processing, and will use this competence in their contribution to WP2 on biomarker discovery in humans, WP4 on validation of biomarkers in humans and WP6 on cross validation and joint analysis. In WP7 on dissemination and exploitation, QUIBIM will lead the development of an exploitation and IPR plan. |
|
| Erasmus University Medical Center (ERASMUS) ERASMUS is the owner of the Rotterdam Study, which is one of the large data sources in the project. ERASMUS will contribute to WP2, WP4 and WP6 in addition to participating in dissemination activities under WP7. |
|
